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Abstract
Malaria is still a major public health problem in Brazil, with approximately 306 000 registered cases in 2009, but it is 
estimated that in the early 1940s, around six million cases of malaria occurred each year. As a result of the fight against 
the disease, the number of malaria cases decreased over the years and the smallest numbers of cases to-date were 
recorded in the 1960s. From the mid-1960s onwards, Brazil underwent a rapid and disorganized settlement process in 
the Amazon and this migratory movement led to a progressive increase in the number of reported cases. Although the 
main mosquito vector (Anopheles darlingi) is present in about 80% of the country, currently the incidence of malaria in 
Brazil is almost exclusively (99,8% of the cases) restricted to the region of the Amazon Basin, where a number of 
combined factors favors disease transmission and impair the use of standard control procedures. Plasmodium vivax 
accounts for 83,7% of registered cases, while Plasmodium falciparum is responsible for 16,3% and Plasmodium malariae 
is seldom observed. Although vivax malaria is thought to cause little mortality, compared to falciparum malaria, it 
accounts for much of the morbidity and for huge burdens on the prosperity of endemic communities. However, in the 
last few years a pattern of unusual clinical complications with fatal cases associated with P. vivax have been reported in 
Brazil and this is a matter of concern for Brazilian malariologists. In addition, the emergence of P. vivax strains resistant to 
chloroquine in some reports needs to be further investigated. In contrast, asymptomatic infection by P. falciparum and 
P. vivax has been detected in epidemiological studies in the states of Rondonia and Amazonas, indicating probably a 
pattern of clinical immunity in both autochthonous and migrant populations. Seropidemiological studies investigating 
the type of immune responses elicited in naturally-exposed populations to several malaria vaccine candidates in 
Brazilian populations have also been providing important information on whether immune responses specific to these 
antigens are generated in natural infections and their immunogenic potential as vaccine candidates. The present 
difficulties in reducing economic and social risk factors that determine the incidence of malaria in the Amazon Region 
render impracticable its elimination in the region. As a result, a malaria-integrated control effort - as a joint action on 
the part of the government and the population - directed towards the elimination or reduction of the risks of death or 
illness, is the direction adopted by the Brazilian government in the fight against the disease.
Background
During the late 1930s, the Northeast Region of Brazil was
invaded by Anopheles gambiae and a severe malaria out-
break, with a 13% fatality rate in a largely immune-naïve
population, astonished Brazilian malariologists and
health authorities. Because of the shipping traffic
between Brazil and Senegal at that time, it was assumed
that the invader came from this African region, probably
in French warships travelling in 70 hours from Dakar to
Natal to conduct meteorological studies preparatory of
the transatlantic flights to be done in the future commer-
cial companies [1]. Organized efforts to eliminate this
very efficient malaria vector succeeded in the first years
of the 1940s. The episode is considered to be one of the
most important and successful Brazilian public health
control campaigns.
It is estimated that in the early 1940s, malaria was a
nationwide problem with around six million people,
approximately 20% of the national population, infected
each year [2]. However, during the late 1950s, a national
and successful campaign, following the eradication aims
dictated by WHO, gained strength in the country,
decreasing malaria to its lowest level by 1960, when only
36,9 thousand cases were registered [3]. Although the
eradication programme of the Ministry of Health in Bra-
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zil - based on DDT spraying on the walls inside the
houses and the use of chloroquine to treat febrile cases -
succeeded in freeing the majority of the country from
malaria transmission by the late 1960s/beginning of the
1970s, it was, however, unable to contain the rapid spread
of the disease in the Amazon Basin, where malaria still
remains a serious health problem [4] (Figure 1).
From the mid-1960's onwards, Brazil underwent a
rapid and disorganized settlement process in the Ama-
zon, which witnessed a huge transformation. Coloniza-
tion programmes, sponsored by the government, resulted
in massive and uncontrolled migration and brought a
new reality for which the area was not prepared. This
migratory movement led to a progressive increase in the
number of reported cases in the country that rose from
52 000 in 1970 to 578 000 in 1989 [3,5-7]. In 1992, the
WHO sponsored a meeting on malaria control at
Amsterdam (Netherlands), pushing Ministries of Health
of countries where malaria was still endemic to adopt
integrated malaria control measures focusing the
decrease of malaria morbidity and fatality rather than its
eradication [8].
The Brazilian National Programme for Malaria Control
(Plano Nacional de Controle da Malária, PNCM), which
h a d  s o  f a r  b e e n  b a s e d  o n  D D T  s p r a y i n g  i n  t h e  i n t r a -
domicile of all houses of the endemic region (goal never
achieved) and the diagnosis and treatment of present and
recent febrile cases, reoriented its actions focusing them
on early diagnosis and adequate treatment of cases. The
policy of increasing the number of health posts able to
perform these tasks started at that time and resulted, for
the first time, in a decrease of the proportion of falci-
parum malaria cases (Figure 1). The highest figures were
recorded in 1999 (637,470 cases), when the government
decided to implement a plan to intensify the actions of
the PIACM (Plano de Intensificação das Ações de Con-
trole da Malária). The new plan had the main goals of
reducing malaria incidence, morbidity (including the
severe forms of the disease) and fatality; to eliminate
malaria transmission in urban areas of the capitals of the
Amazon States and to maintain the interruption of the
disease transmission in places where this has been
achieved. The Brazilian authorities also followed the rec-
ommendation of focusing the control strategies in the
individuals rather than in the environment [9]. For this,
the Secretary of Health Surveillance (SVS) of the Ministry
of Health targeted an important expansion of the network
of diagnosis/treatment stations in the Amazon. The fig-
ures were 1 182 diagnostic laboratories, 2,656 malaria
control agents and around 2,4 × 106 blood examinations
Figure 1 Number of malaria cases registered yearly from 1960 to 2009 in the Brazilian Amazon according to the Plasmodium species re-
sponsible. The great increase of malaria cases during late 70's and 80's was due to massive and uncontrolled migration to the Amazon region of peo-
ple attracted by colonization programmes, sponsored by the government. The highest figures were recorded in 1999 (637 470 cases) when the 
government decided to implement the Plan for Intensification of Actions for Malaria Control (PIACM) in high-risk areas focusing on the early diagnosis 
and treatment of the cases. The circle with the intersection lines shows that the present number of malaria cases corresponds to the figures recorded 
in 1983. Notice also the progressively decreasing proportion of cases due to P. falciparum after 1988. In 1990 44.3% of cases were due to P. falciparum 
and the situation of the most prominent predominance of P. vivax transmission was reached in 1999 (only 18.6% of cases being due to P. falciparum).
0
100
200
300
400
500
600
700
6 0 6 1 6 2 6 3 6 4 6 5 6 6 6 7 6 8 6 9 7 0 7 1 7 2 7 3 7 4 7 5 7 6 7 7 7 8 7 9 8 0 8 1 8 2 8 3 8 4 8 5 8 6 8 7 8 8 8 9 9 0 9 1 9 2 9 3 9 4 9 5 9 6 9 7 9 8 9 9 0123456789
Total cases
P. falciparum
P. vivax
 	

	





















Oliveira-Ferreira et al. Malaria Journal 2010, 9:115
http://www.malariajournal.com/content/9/1/115
Page 3 of 15
in 1999 as compared to the 3,492 diagnostic laboratories;
48,849 malaria control agents and around 2.8 × 106 blood
examinations recorded in 2009 [10]. Apparently, the
strategy of active case detection in some highly endemic
areas, such as those in which Yanomami Indians were liv-
ing, led to a sustained control of the disease [11]. How-
e v e r ,  t h e  i m p a c t  o f  t h i s  s t r a t e g y  b y  i t s e l f  c a n n o t  b e
analyzed properly, because other interventions were
applied at the same time as part of the PIACM, corrobo-
rating the idea that isolated interventions are not enough
for the control [10].
However, a recrudescence of malaria transmission
occurred in some localities of the Amazon and the inci-
dence rose again from 2003 to 2005, bringing the figures
to a situation almost comparable to that registered in
1999. The analysis of the reasons for this increase points
to a multifactorial genesis of the phenomenon. This
would involve climatic changes and migratory move-
ments due to a disorderly occupation of the outskirts of
large cities in the region as a result of agrarian reform
projects and the consequent deforestation for logging,
cattle ranching, agriculture, as well as for unofficial settle-
ments. Poor performance in the implementation and
administration of the actions prescribed by PNCM at the
level of municipalities also contributed to increased
transmission. Another contributor is the increase of the
mosquito vector population as a result of an inadequate
management of the environment. One example is the
abandoned tanks used for fish-farming in the backyards
of homes or on the outskirts of several towns in the Ama-
zon region, as in Manaus, where they were common. To
meet the new dynamics of transmission, the Ministry of
Health initiated wide-ranging multi-sector mobilization
of forces, mainly the health managers in states and
municipalities in the Amazon region, to coordinate popu-
lation movements and to prioritize surveillance, preven-
tion and control of malaria on their agendas. The effects
of this joint effort are reflected in a substantial reduction
of cases from 2006 onwards. The number of cases fell
thereafter to 456 000 in 2007. The last available data show
that, in 2008, an additional 31% reduction in the number
of cases brought the figures (314,420 cases) to a situation
comparable to that of 1983 (Figure 1). The Amazonian
Annual Parasitological Index (API, number of cases/
thousand inhabitants) fell also from 31.9 in 1999 to 12.8
in 2008 [10]. In order to take advantage of this kind of
results and information to improve and consolidate the
malaria control actions, it is necessary to try to analyze
and understand results that indicate success, as is done
when facing failures of the control measures and worsen-
ing of the malaria situation. The Coordination of the
National Control Programme considers that the strength-
ening of the local management capabilities, through the
continued expansion of the diagnosis and treatment net-
work, may account for the sustained reduction of cases
from 2006 onwards. This produced a decrease in the rates
of disease severity as well as the reduction of the numbers
of municipalities at (high, medium and low) risk in the
Amazon (Figure 2). According to the PNCM, the absence
of such approaches may explain the concentration of
cases in some counties, where management has not pri-
oritized the control of malaria, or other conditioning fac-
tors.
It is also important to point out that, although Anophe-
les darlingi, the main mosquito vector, is present in about
80% of the country, the incidence of malaria in Brazil is
almost exclusively (99.8% of the total number of cases)
restricted to the Amazon Region, where a number of
combined factors favor disease transmission and impair
the use of standard control procedures (Figure 2)[3]. The
number of cases in the nine States of the Brazilian Ama-
z o n  h a s  f l u c t u a t e d  o v e r  t h e  y e a r s ,  i n c r e a s i n g  i n  s o m e
states where new settlements projects and gold mining
activities are implemented. In addition, the transmission
inside the region is not regularly distributed, since 57
(7.1%) out of the 807 municipalities in the Amazon states
account for 80% of the total registered malaria cases and
three of these accounts for 18% of the Amazonian cases
[10]. In addition, and unfortunately, the disease seems to
be concentrated not only in localities, but also in some
groups of individuals. Although the overall incidence of
malaria is decreasing, an augmented proportion of the
disease in women (34,9% in 2003 to 38.6% in 2008) and
children below 10 years of age (22,0% in 2003 to 25,2% in
2008) has been recorded in the last years [10]. The rea-
sons remain to be determined but environmental factors,
such as proximity of houses to mosquito-breeding places,
could be involved. A follow-up of a cohort of around
6,400 women at the Coari Municipality (Amazonas - Bra-
zil) in 2001 and 2002 has shown that only 0.1% of parasi-
tologically-negative women and 92% of the positive ones
reported at least one past episode of malaria[12]. The
economical development of the new borders in the
Northern Brazil had a great impact and could explain the
maintenance of the disease in cities like Manaus, a city of
two-million inhabitants, with a tax-free status, which
attracts thousands of workers from several parts of the
country and abroad [13].
Any decision-making process depends on obtaining
robust data on the parameters to be monitored. For this,
it is necessary to implement an epidemiological surveil-
lance system and to permanently strengthen and improve
local structures to generate and record standardized
information that can guide the decisions, both at a local
and national level. One positive aspect of the PNCM is
the way the management of epidemiological information
and the consolidation of routine work are conducted. Its
information system (SIVEP-Malaria) is now highly devel-Oliveira-Ferreira et al. Malaria Journal 2010, 9:115
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oped and operates with a high coverage. All cases of
malaria are included individually in a national database,
with inputs from a network at the local level. The infor-
mation recorded in the system is sent rapidly, via the web,
to the regional levels and to the headquarters of the
PNCM in Brasília. Automated reports are available on-
line permanently, with input of approximately 42% of
cases in eight days and 82% of cases in less than 30 days
after the end of the corresponding month. Reports pro-
duced after 60 days of the period closure may cover more
than 95% of cases. The SIVEP-Malaria database contains
variables that allow the evaluation and selection of opera-
tional and epidemiological indicators, for which there are
already pre-established routine analysis by the PNCM,
and that are useful for monitoring and evaluating the sit-
uation. The system also allows monitoring of the scatter-
ing parameters of transmission in each city, which is
useful to evaluate the degree of coverage of the diagnosis,
treatment and use of insecticide-treated bed nets. Fur-
thermore, the diagnosis offer versus the demand of cases
can also be analyzed, in order to guide and adjust the
diagnosis network. SIVEP provides also data related to
the dispensing of drugs and the proportion of treatment
failures among the diagnosed cases. The simplicity of the
form guarantees a good quality of data and it is estimated
that the system has a good sensitivity, since all the medi-
cation to treat malaria is distributed free by the Ministry
of Health, through the reporting of cases. Nevertheless,
the localized analysis of the system peculiarities in each
municipality makes it possible to identify a heterogeneity
of the general characteristics.
A project, recently submitted by the Brazilian Govern-
ment (PNCM-Ministry of Health) and approved by the
Global Fund, focuses the investment in epidemiological
intelligence in strategic localities in the Brazilian Amazon
and has the potential to change the history of malaria in
Brazil. The goal of the project is to support and improve
the capacity of local health services in order to enhance
the understanding of the dynamics of the disease trans-
mission and to conduct, with greater efficiency, the man-
agement of the intervention measures of the project and
the control actions of the regular programme. The proj-
ect aims to decrease morbidity and mortality in the Ama-
zon region and the main expected result in the five-year
project is a 50% reduction in the number of malaria cases
in the 47 municipalities of the Amazon region, which had
accounted for 70% of malaria cases in Brazil in 2007. The
methodology is based on the strengthening of two recog-
nized intervention measures: a) ensure early diagnosis
and the administration of a timely treatment with effec-
tive drugs, amplifying the diagnosis network and improv-
ing the drug management, and b) quickly achieve high
coverage of prevention with long-term insecticide-
treated bed nets. The project is committed to concentrate
in epidemiological intelligence and efficient management
at the local level. This would be based on the establish-
Figure 2 Areas of malaria transmission in Brazil according to the Annual Parasitary Index (API) in the years of 2000 and 2008. The Amazonian 
Annual Parasite Index (API, number of cases/thousand inhabitants) indicates success and failures of the control measures in some counties. Low API: 
< 10 cases; medium API: 10 to 49.9 cases; high API: > 50 cases. The distribution of transmission is not regular since 57 (7.1%) out of the 807 municipal-
ities in the Amazon states concentrate 80% of the total registered malaria cases and only three (0.4%) of them accounts for 18% of the Amazonian 
cases.
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ment of a routine analysis for decision-making in close
coordination with operating and management systems at
all government levels (states and municipalities). This
would also promote community organization and mobili-
zation to facilitate participation in specific malaria con-
trol actions and improve acceptance of control measures
by the communities.
In addition, we must emphasize the Brazilian capabili-
ties of large-scale manufacturing of antimalarials. For
instance, the association of artesunate/mefloquine pro-
duced by Farmanguinhos (Fiocruz) after a joint action of
the Brazilian Ministry of Health and the Drugs for
Neglected Diseases iniative (DNDi), is presented in dos-
ages for adults and children, therefore facilitating drug
intake and increasing adhesion to treatment. Currently,
the State of Acre, in the Amazon, and all the States of the
Extra-Amazonian Region successfully use the drug.
It is important to point out that the use of tools, such as
artemisinin-based combination therapy, impregnated bed
nets and rapid diagnostic tests, have not yet been evalu-
ated in an integrated manner in a horizontal health sys-
tem, such as the one offered in the Brazilian Amazon.
This may indicate that the elimination of the disease in
the country can be effectively achieved in the future. On
the other hand, the analysis of available data, when the
figures of malaria in Brazil achieve the situation of resid-
ual transmission in the future, may indicate the need of
readapting the PNCM policy in view of the elimination of
the disease in the Amazon Region and in the whole coun-
try.
Although the PNCM has succeeded in reducing drasti-
cally deaths, severe cases, hospitalizations and the
national incidence of the disease, it seems important to
consider its vulnerability, as the programme is based fun-
damentally on the diagnosis and treatment. In view of the
potential emergence of P. falciparum resistance to
artemisinin-based combination therapy and the absence
of alternatives drugs, research programmes to identify
new drugs that may replace the present ones are
extremely important and urgently needed.
The changing pattern of P. falciparum and P. vivax 
transmission
In Brazil, malaria is caused by three species of Plasmo-
dium: P. vivax (that accounts for 83,7% of the registered
cases), P. falciparum (causing 16,3% of the cases) and P.
malariae  (a small proportion of cases). No autochtho-
nous transmission of P. ovale and P. knowlesi occurs [10].
Leônidas de Mello Deane, one of the most important Bra-
zilian and world malariologists, used to say that the
Superintendência de Campanhas (SUCAM, the national
organization in charge of malaria control in Brazil, until
its fusion with the Fundação Serviços Especiais de Saúde
Pública, SESP, giving place to the Fundação Nacional de
Saúde - FNS or FUNASA) had "eradicated" P. malariae
from Brazil in the 1980s simply by switching the method
of diagnosis from thin to thick smear, the only official
method for malaria diagnosis in Brazil. Indeed, with this
procedure it is not possible to assess the morphology of
infected red blood cells and the parasite-altered shape
can lead to a mistaken identification of P. malariae as P.
vivax. Therefore, the failure to report P. malariae in
endemic areas is not surprising. Studies on antibody
response to P. malariae CS protein and the use of nested
polymerase chain reaction suggest that this parasite could
possibly be more prevalent in scattered areas, at least in
the populations studied in Rondônia, Amazonas and Pará
States [14,15]. However, no case of P. malariae infection
was found by PCR among febrile patients in Manaus [16].
Even if considering that the incidence of P. malariae in
Brazil may be underestimated, it is worth mentioning
that predominant incidence of P. vivax malaria is a quite
recent phenomenon (since the early 1990s) and results
from, or has been at least very probably reinforced by, the
pressure exerted by the PNCM aiming at the early diag-
nosis and treatment of cases. Indeed, since P. falciparum
gametocytes appear in the peripheral blood only after 8
to 10 days of infection, prompt diagnosis and adequate
treatment of the falciparum malaria cases can interrupt
parasite transmission more efficiently, than in the case of
P. vivax malaria, in which gametocytes are already pres-
ent in the circulation in the first three days of blood infec-
tion [17]. Thus, the relative incidence of the two main
Plasmodium  species transmitted in Brazil was around
50% each in 1988. This changed from 1990 onwards
(when 44.3% of cases were due to P. falciparum), reaching
the situation in 2009 when P. vivax has become the pre-
dominant species (only 16,3% of cases being due to P. fal-
ciparum)(Figure 3).
The decreasing occurrence of severe malaria in Brazil
Plasmodium vivax is thought to cause little mortality but,
as P. falciparum, it accounts for a vast amount of morbid-
ity and for a huge burden on the prosperity of endemic
communities. Probably as a result of the early diagnosis
and treatment of the cases and of the decrease in P. falci-
parum transmission, the number of hospitalizations due
to malaria dropped (53,450 in 1994 to 18 037 in 2000 and
4,442 in 2009) as did the number of registered deaths
attributed to the disease (from 897 in 1984 to 58 in 2009),
together with the fatality rate (from 0.038% in 2000 to
0.013% in 2009) in the Amazon (Figure 4). This is proba-
bly a direct result of the early diagnosis and treatment of
the malaria cases as a consequence of the already men-
tioned expansion of the network of Laboratory and
Health Agents in the Amazon. In fact, 59% of all malaria
cases registered in 2008 in the region were treated in the
first 48 hours after appearance of symptoms [10], dimin-Oliveira-Ferreira et al. Malaria Journal 2010, 9:115
http://www.malariajournal.com/content/9/1/115
Page 6 of 15
ishing both the transmission and the occurrence of com-
plicated cases in endemic areas.
In one illustrative example of the present situation, as
far as malaria morbidity in Brazil is concerned, Fernandes
et al [18] studied 127 P. falciparum and 74 P. vivax
malaria patients in two localities (Belém and Paragomi-
nas) of the Amazonian State of Pará and could find only
one case of severe anaemia (associated to P. vivax and not
to  P. falciparum infection). No other malaria patient
enrolled in the study was hospitalized due to anaemia or
for any other reason. The low frequency of hospitaliza-
tion observed during the period of the study (2001 to
2003) was in accordance with the overall picture recorded
for the state of Pará in the same period, when there was a
sharp reduction in the total number of malaria cases
(279,303 in 2000 and 123,490 in 2003) and in the fre-
quency of hospitalization (3.3% in 2000 and 2.6% in 2003)
[19]. The absolute number of hospitalized patients from
2000 to 2003 in Belém dropped drastically as well (140
hospitalized patients in 2000 and 49 in 2003) and particu-
larly in Paragominas (275 in 2000 and only six in 2003). In
the same way, the mortality due to malaria in 2001 to
2003 was low, with a total of 119 fatal cases out of 458,305
malaria cases [0.26 fatal outcomes per 1 000 malaria
cases, or 10.2 deaths per 1 000 hospitalized patients [Rui
Bráz and Carlos José Mangabeira-Silva (PNCM-SVS/
MS), personal communication]. Similar data were pre-
sented by Caicedo et al [20], who found that severe anae-
mia was rare amongst patients from two distinct malaria
endemic areas in Manaus (Brazil) and Tumaco (Colom-
bia).
In spite of the decreasing severity of malaria observed
in Brazil in the last years, one point that merits to be
emphasized, is that, precisely as a result of the concentra-
tion of malaria in the Amazon region, general practitio-
ners outside the Amazon region are much less alert to
consider the diagnosis of malaria, when facing a febrile
patient. Migration and international travel require per-
sonnel with specific expertise, highlighting the impor-
tance of the specialty of Infectious Diseases and the
sentinel surveillance of febrile travelers. One illustrative
example would be the already reported frequent confu-
sion of malaria with dengue in the city of Rio de Janeiro
[21]. Visitors from Africa might die of falciparum malaria
about seven days after the beginning of the symptomatol-
ogy, with more than half of all erythrocytes parasitized
[22]. These are probably the reasons why malaria lethality
is more than seventy times higher in this region (1,27%)
than in the Amazon (0,018%)[10]. It is noteworthy that
most of the travelers' clinics in Brazil are concentrated in
Rio de Janeiro and São Paulo states.
In summary, the inversion of the P. falciparum/P. vivax
cases ratio in Brazil in the last two decades was a major
achievement of the National Control Programme, leading
to a substantial decrease in the number of deaths. How-
ever, this may be troublesome regarding the future per-
spectives of eliminating malaria in Brazil, since policy-
makers are less prone to privilege investments in a dis-
ease with low fatality rates and with a massive incidence
outside the economic axis area of the country. Some
neglected effects of the 'benign' P. vivax infection must be
considered because they may compromise the develop-
ment of endemic countries, such as the impact upon
school performance, as recently shown in children from
an endemic area in the Amazonas State [23]. In addition,
vivax malaria may not always be benign [10].
Figure 3 Evolution of the proportion of malaria cases due to Plas-
modium falciparum in the Amazon from the year of 1999 to 2009. 
Since P. falciparum gametocytes only appear in the peripheral blood 
after 8 to 10 days of infection, prompt diagnosis and adequate treat-
ment of the P. falciparum malaria cases can interrupt parasite transmis-
sion more efficiently than it can do in the case of P. vivax malaria, in 
which gametocytes are already present in the circulation in the first 
three days of blood infection [15]. * Beginning of the new therapy ar-
temether/lumefantrine, the first line regimen for non-complicated fal-
ciparum malaria in Brazil. Source: Sivep - Malaria - Data updated on 
September 9th, 2008.
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Figure 4 Malaria fatality rates and number of hospitalizations 
due to the disease in the Brazilian Amazon from 1999 to 2009. The 
number of hospitalizations due to malaria in the Brazilian Amazon 
dropped from 53,450 in 1994 to 18,037 in 2000 and 4,442 in 2009 as did 
the number of registered deaths attributed to the disease (from 897 in 
1984 to 58 in 2009) as well as the fatality rate (from 0.038% in 2000 to 
0.013% in 2009). The malaria cases seen in Brazil are being rapidly diag-
nosed and treated (59% of all malaria cases in 2008 registered in the 
Amazon were treated in the first 48 hours after appearance of symp-
toms, Malaria/SVS/MS, 2009), diminishing both the transmission and 
the occurrence of severe cases.
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Unusual clinical complications associated with P. vivax in 
the Brazilian Amazon
Plasmodium vivax infection is generally recognized in
the literature as a benign disease, despite triggering fever
with a lower peripheral parasitaemia, as compared to P.
falciparum [24]. However, in the last few years a pattern
of unusual clinical complications with fatal cases associ-
ated with P. vivax have been reported in Brazil and is a
matter of concern for Brazilian malariologists [25,26]. It
is difficult to assume that there has been a worldwide
increase of severity associated with P. vivax infection.
Although most of the publications had previously been
biased towards P. falciparum infection and its associated
severity in the African continent, where most of the
deaths are concentrated, more recently some attention
has been devoted to the burden of the complicated P.
vivax disease in Southeast Asia [27] and Latin America
[28].
In Brazil, importantly and curiously, paralleling the
increase in the proportion of P. vivax malaria recorded
from the middle of 1980s to the beginning of the 1990s,
an increase in the frequency of unusual clinical complica-
tions in P. vivax infected patients has been observed in
the Amazon. According to the official statistics, from
1998 to 2008, 234 deaths related to P. vivax infection were
reported in the Brazilian Amazon [10,29]. However, one
must keep in mind that the description of a severe case
and, even more, of a fatal case of P. vivax malaria
requires, as a sine qua non condition, the confirmation of
the involved species using a highly sensitive approach
(e.g., PCR) to eliminate the possibility of a mixed (P. falci-
parum/P. vivax) infection and to rule out the presence of
other simultaneous acute infectious diseases (e.g., den-
gue, yellow fever and other Amazonian virus - such as
Oropoupouch and Mayaro, leptospirosis, typhoid fever,
sepsis), as well as other chronic diseases, such as sickle
cell anaemia, which may decompensate as a result of the
P. vivax infection [25]. Likewise, fatal cases must ideally
be submitted to a full autopsy allowing the characteriza-
tion of its major anatomo-pathological findings. Despite
representing a very low fatality rate, such severe cases
were not reported when P. falciparum was the predomi-
nant species in Brazil. They may be associated to an
increased exposure of non-immune population to this
species, leading to the occurrence of severe P. vivax infec-
tion, similar to what was observed in the north-west of
India, in Rajhastan, where severe P. vivax cases started to
show up only after the inversion in the P. falciparum/P.
vivax cases ratio [30,31].
The proportion of hospitalized cases due to P. falci-
parum decreased from 29% in 2003 to 25% in 2008, those
due to an increase of P. vivax from 38% to 49% [10]. While
the number of lethal cases of vivax malaria is stable since
2001 (around 21 cases/annum), the decrease in malaria
t ra ns m is si on a nd in t he  a bsol ut e  n u m ber  of  r egist e r ed
cases of vivax malaria since 2005 result in a mild but reg-
ular increase in the fatality rate in the last years, the high-
est rate having been observed in 2008 (0.008%)(Figure 4).
Manaus, the capital of the Amazonas State, is one of the
three municipalities that, together with Porto Velho
(Rondônia State) and Cruzeiro do Sul (Acre State)
accounted for about one fifth of the total number of cases
notified in Brazil in 2008 [10]. In Manaus, the Fundação
de Medicina Tropical do Amazonas (FMT-AM) - that
serves as a reference centre for health care and research
on tropical diseases and diagnoses - treats around 30% of
the malaria cases seen in this municipality. In Manaus,
the total number of hospitalized P. vivax malaria cases as
well as the proportion of the hospitalized cases due to
this species (in relation to P. falciparum) seems to be
increasing in the FMT-AM [32]. The major complication
found in patients with P. vivax infection is thrombocy-
topenia, which accounts for 20% of the admissions to this
tertiary care hospital in Manaus [26,33]. In the majority
of the cases, severe thrombocytopenia (< 50 000 plate-
lets/mm3) is not associated with coagulation disorders,
such as disseminated intravascular coagulation [34]. In
Manaus, severe thrombocytopenia was found in 8.9% of
the patients with P. vivax infection, with only bleeding in
one fourth of them (Lacerda MVG, unpublished data).
The clinical relevance of this haematological complica-
tion, however, needs further clinical studies, as well as for
P. falciparum, since there is no reported fatal case of
malaria presenting exclusively with severe thrombocy-
topenia. Other relevant clinical complications include
patients developing immune thrombocytopenic purpura
after curing the infection [35] and splenic haematoma
[36]. In non-endemic areas of malaria in Brazil, such as
São Paulo, severe cases of P. vivax infection are being
reported in travelers [37], and thrombocytopenia is often
misattributed to dengue infection in Rio de Janeiro,
where the disease is endemic [38].
At the FMT-AM, in a retrospective study from 2001 to
2002, applying the WHO criteria of malaria severity (tra-
ditionally used for P. falciparum malaria), 12.8% of the
patients were diagnosed as having severe P. vivax malaria
(43 out of 336 patients hospitalized with P. vivax malaria
during the period). The clinical complications were very
similar to those associated with P. falciparum infection,
e.g., hyperbilirrubinaemia, severe anaemia, acute renal
failure, pulmonary edema and algid malaria [39]. In a
series of cases with the parasitological diagnosis of P.
vivax infection, which evolved to death in the same insti-
tution and were submitted to a full autopsy, the major
findings were acute tubular necrosis, pulmonary edema
and pneumonia (Lacerda MVG, unpublished data). Most
of the patients who died presented other co-morbidity
that could have contributed to the death, such as chronicOliveira-Ferreira et al. Malaria Journal 2010, 9:115
http://www.malariajournal.com/content/9/1/115
Page 8 of 15
liver disease, cardiac disease and G6PD deficiency. Series
of severe cases have also been reported in other endemic
areas for P. vivax malaria [30,40], but no standardized cri-
teria are being routinely used for the clinical description
of such cases in the literature.
Although this is not in the scope of this overview, it is
important to briefly consider some aspects of the treat-
ment of P. vivax malaria, which is no longer a simple task
in many parts of the world, including Brazil. For instance,
the radical cure of hypnozoites with primaquine (the only
hypnozoiticidal drug currently approved for clinical use),
almost always feasible with the shorter regimen of 30 mg/
day for seven days in adults currently used un Brazil, may
require the classical long-term (14 day) regimen [41].
With the increase in the number of P. vivax infections,
the widespread use of primaquine for the radical cure
may trigger severe complications (such as haemolysis and
methaemoglobinaemia) in patients deficient for G6PD,
which frequency is around 3% among males in Manaus
[42]. These complications can be mistaken as a complica-
tion of P. vivax per se [43].
There is also in vivo evidence for the resistance of P.
vivax to chloroquine in the Brazilian Amazon [44]. The
resistance to chloroquine was firstly reported in Manaus
in 1999 [45] and more recent data, from studies con-
ducted in the context of the RAVREDA (Amazonian Net-
work for Surveillance for Resistance to Antimalarial
Drugs) with a proper follow-up of patients exclusively
using chloroquine and in whom the drug plasma concen-
tration was performed, seem to confirm such an observa-
tion [46]. However, since chloroquine plus primaquine,
the drug association used for the radical cure of P. vivax
infection, have a synergistic action [47], further studies
are needed before any definitive conclusion can be pro-
posed. Such studies should include non-endemic areas
where the chance of reinfection is minimal and the
potential for monitoring real resistance to both drugs is
enhanced.
Malaria outside the Amazon region and the "bromeliad-
malaria"
As an expected consequence of the existence of some
thousands of malaria cases in the Amazon basin, a few
cases do occur also outside the area of active transmis-
sion. Some of them correspond to autochthonous cases of
malaria transmitted and maintained in small foci of
transmission with very specific characteristics, such as
those reported in the Atlantic Forest. The historical series
of autochthonous cases outside the Amazon region is
presented in Figure 5, showing a huge increase in the
numbers in 2002 due to an outbreak of P. falciparum
malaria occurred in the Ceará State, north-eastern Brazil.
Considering the State of Rio de Janeiro, where the
headquarters of Fundação Oswaldo Cruz and CPD-Mal
(the Reference Center for Malaria at the Secretary of
Health Surveillance at the Ministry of Health) are located,
a total of 1,505 malaria cases were reported from 1990 to
2008 (79 cases/year). Rio de Janeiro is the most visited
city in Brazil (two million of tourists annually) and the
home of 20% of all Brazilians who travel abroad for leisure
or business. Probably as a result of this, most of malaria
cases seen in the city are expected to be imported from
the Amazon region and Africa. However, in the 2001-
2008 period, 30% of the 29 reported autochthonous cases
in Rio de Janeiro originated from Nova Friburgo, a moun-
tain region in the Atlantic Forest. In the 2006-2008
period, three cases, diagnosed (by thick blood Smear, and
PCR) as P. vivax malaria, came from localities situated
between the municipalities of Nova Friburgo and Guapi-
mirim at the "Serra dos Órgãos", also in the Atlantic
Region. Patients presented at the Acute Febrile Diseases
Outpatient Clinics of the Instituto de Pesquisa Clinica
Evandro Chagas (a branch of the CPD-Mal at Fiocruz)
with low parasite (P. vivax) counts and mild symptoms
including low-grade (< 38°C) fever and splenomegaly
[38]. Mild atypical symptomatology and very low parasi-
taemia was also the predominant presenting form of the
disease in the autochthonous P. vivax malaria reported in
inhabitants of two parks in the Atlantic forest of the São
Paulo State between 1990 and 2000 [48,49]. Little is
known about the factors involved in the chain of native
transmission of malaria in the Atlantic region and malaria
outbreaks in the Atlantic forest of Rio de Janeiro are not
new events. Serological and entomological surveys per-
formed in 1993 and 1996 in a village situated in a moun-
tain valley: Rio Bonito in Rio de Janeiro state, where an
outbreak of vivax malaria had occurred, suggested that
Anopheles (Kerteszia) cruzii was a potential vector of
malaria in this region [50]. At that time, one of the
hypotheses was that members of a group of religious
sects originating from the Amazon and constantly visit-
Figure 5 Number of cases of autochthonous malaria seen outside 
the Amazon region. The peak registered in 2002 is due to an outbreak 
of Plasmodium falciparum malaria observed in the State of Ceará, 
Northwestern Brazil. Cases seen outside the Amazon are mainly due to 
the transmission by Anopheles (Kertezia) occurring in the Atlantic forest 
possibly maintained by the involvement of infection of monkeys.
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ing the Amazon region could be responsible for the intro-
duction of malaria in the district of Lumiar (Rio de
Janeiro). The installation of a timber factory in Friburgo,
working with products of trees brought from the Amazon
region, points to another possibility for carrying mosqui-
toes as foci of infection.
Deane [51] suggested that simian Plasmodium species
could be responsible for these cases of malaria known as
"bromeliad-malaria" in forest areas, where monkeys of
the genera Allouata and Cebus and the Anopheles (Kerte-
sia) cruzii and Anopheles (Kertezia) bellator, which breed
in the water collections formed inside the bromeliads, are
present. The presence of malaria in people coming into
such areas of dense forest could ensure both simian and
human malaria transmission. Duarte and coworkers [52]
showed the occurrence of malaria parasites and serologi-
cal responses against asexual forms and synthetic pep-
tides mimicking the immunodominant epitope of the
circumsporozoite protein (CS protein) of human malaria
parasites in wild monkeys from areas of autochthonous
human malaria. The existence of P. vivax variants and
simian malaria in the Atlantic forest of Rio de Janeiro and
Espirito Santo States also points to the possibility that
monkeys could be the natural reservoir for malaria in the
Atlantic forest and explain the autochthonous cases reg-
istered (Figure 6)[48,50,53]. Recent studies have shown
that the simian malaria P. knowlesi in the human host is
not rare, is widely distributed and can result in severe dis-
ease and death in humans, particularly in areas inhabited
by the natural macaque host [54]. Taken together these
data support the view that malaria transmission from
neotropical primates to humans, and vice versa, may also
occur more frequently than currently believed, both in
the Amazonian rainforest and in the Atlantic forest.
The interruption of transmission of the "bromeliad-
malaria", which occurred during the years 1980 to 1982 in
the state of Santa Catarina - southern Brazil, was impor-
tant and a good example that alternative control mea-
sures may be required to the control of residual malaria in
an given area [55]. The transmission was restricted to two
municipalities (São Francisco do Sul and Taquari) in that
state and had never been interrupted, despite many
efforts. In these two municipalities with a population of
thirty thousand people, one thousand and six hundred
autochthonous cases occurred each year, mainly in adults
males under 50 years old. The transmission was seasonal,
from November to April and all cases were due to P.
vivax. The main vector was An. cruzii, which usually bites
animals and humans outside houses. The use of DDT
spraying inside the houses - a traditional measure in the
control of malaria - was rejected by a high proportion of
people, because its ineffectiveness, and because other
interventions previously used, such as mechanical and
chemical massive destruction of bromeliads, were also
ineffective. The hypothesis that monkeys could be an
eventual reservoir maintaining the parasites from May to
October was discarded since they were not found in the
area. Therefore, other hypotheses were considered to
explain the maintenance of the circulation of parasite in
humans in those localities. They included the presence of
either asymptomatic P. vivax infections - patients with
very low parasitaemia undiagnosed by microscopic
examination - or of a P. vivax strain (already described in
temperate climates) with long-term incubation period. A
sero-epidemiological survey was performed with the aim
of identifying parasite-carriers needing to be treated [56].
In 1980, around twenty seven thousand blood samples
were collected on filter paper and sent to be processed in
the SUCEN Laboratory at São Paulo. About five hundred
people presented antibody (as revealed by anti-human
total Ig antibodies) titres over 1:64 and were treated with
chloroquine plus primaquine. In the following year, only
twenty cases were diagnosed. In 1982, the sero-epidemio-
logical survey was repeated, and two hundred cases were
considered positive, with IgM/IgG over 1:64. They were
treated and until now, about 27 years later, no more
autochthonous cases were registered in the area.
If, on the one hand, studies conducted in the neigh-
bouring states of São Paulo and Espírito Santo confirmed,
using serological or molecular approaches, the asymp-
tomatic infection by Plasmodium  in areas outside the
Amazon region, the lack of investigation of indigenous
malaria cases in the state of Rio de Janeiro, on the other
hand, does not give any information on what actually
happens in the region (Figure 6). Further investigations
are needed to confirm the presence of asymptomatic
Plasmodium-infected individuals in the Atlantic region,
since transfusion malaria is rarely diagnosed, but does
occur and can become an important concern to medical
services and health authorities [57].
Finally, it is important to emphasize to those involved
in giving international travel advice that, excepting for the
examples given above, which concern specific localities of
the Atlantic forest and must be considered rare events,
malaria transmission does not occur outside the Brazilian
Amazon. Therefore, anti-malarial chemoprophylaxis is
neither needed nor recommended by the Brazilian Minis-
try of Health or the WHO to those visiting exclusively
areas outside the Amazon Region. Thus, the visitors
attending the Olympic Games of Rio de Janeiro in 2016
will not need to be submitted to the side effects of anti-
malarials throughout their stay in the city.
Some information arisen from the study of the naturally 
acquired immunity
The pattern of malaria transmission in Latin America is
different from that in the endemic areas of Africa. In Bra-
zil, malaria is endemic in the Amazon region and is fre-Oliveira-Ferreira et al. Malaria Journal 2010, 9:115
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quently associated with migration movements of non-
immune individuals to areas where malaria is endemic.
The population exposed to malaria in these areas, regard-
less of age, is vulnerable and infections tend to be fol-
lowed by clinical symptoms [6,58]. For a long time,
asymptomatic cases have been considered rare in Brazil
[59]. However, asymptomatic infection by P. falciparum
and P. vivax were detected in studies in the states of Ron-
donia and Amazonas, suggesting that subjects exposed to
malaria in Brazil also develop acquired resistance to clini-
cal malaria despite the epidemiological profile different
from the one seen in Africa [60-63].
It is well-established that acquired clinical immunity to
P. falciparum malaria depends on long-term repeated
exposure to the parasite, a conclusion based on the obser-
vation that effective natural immunity to this species is
restricted to areas of high level of transmission and ende-
micity, where age has always been considered to reflect
the degree of exposure. It is now known, however, that
non-immune adult migrants can naturally acquire rea-
sonable clinical immunity more rapidly and efficiently
Figure 6 The Brazilian Biome Map and location of Research Centres. The Amazon region covers 40% of the surface of South America and 5% of 
the surface of the world, and 61% of its territory is in Brazil. It has the largest hydrographic network on earth, covering 20% of the worlds fresh water 
reserves and shelter the largest number of life forms on earth; the Atlantic forest (seasonal semideciduous forests) is the third largest Brazilian biome 
that stretches for about 4 000 km along the Atlantic coast between Rio Grande do Norte and Rio Grande do Sul; the "Caatinga" (semiarid steppe of 
Northeast Brazil) is located on the north-east coast is the largest dry forest region in South America and characterized by a semi-arid climate, low and 
unregular rainfall, fertile soils and an apparently dry vegetation; the Cerrado (Brazilian Savanna) is located on the large plateau that occupies the central 
highlands. Influenced by the four surrounding biomes, the fauna and flora of the Cerrado is extremely rich and the climate is hot and semi-humid; the 
Pantanal (Brazilian wetlands) is located in the watershed of the Upper Paraguay Rivers the largest area of fresh water marshes in the world, shared 
between Brazil (60%), Bolivia and Paraguay. The Pampas are the fertile South American lowlands in the southernmost end of Brazil, the climate is mild 
and contain unique wildlife because of the different terrains around it.Oliveira-Ferreira et al. Malaria Journal 2010, 9:115
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than children, probably reflecting a different maturity of
the immune system [64].
Studies on acquired immune responses against P. falci-
parum  of individuals naturally-exposed who live in
endemic areas of Brazil show that individuals primed
against P. falciparum in their natural habitat, present a
very diverse array of responses against P. falciparum anti-
gens, varying from low to high B and T cell responses and
indicating that the immune response to most of antigens
can be used to assess malaria transmission in epidemio-
logical surveys. Very few of such studies show an associa-
tion with clinical immunity [65-74].
Evidence that the protective immunity to P. falciparum
malaria is associated with different classes and subclasses
of antibodies reveals the importance of considering the
quality of the response. In Brazil, analysis of the antibody
isotypes specific for several P. falciparum proteins
revealed that all four IgG subclasses are present and, for
some proteins such as the N-terminal region of the p126
protein, individuals with higher levels of anti-Nt47 cyto-
philic IgG antibody had significantly lower parasitaemia
l e v e l s  [ 6 8 ] .  I n  c o n t r a s t ,  p l a s m a  c o n c e n t r a t i o n s  o f  I g G
against a detergent-soluble extract of P. falciparum sch-
izonts, the concentrations of anti-parasite antibodies of
all subclasses increased with age. There was no correla-
tion between age and the proportion of cytophilic anti-
bodies [75] and no major difference was observed in IgG
subclass distribution of antibodies to the polymorphic
block 2 and the 19-kDa C-terminal domain MSP-1
between symptomatic, and asymptomatic parasite carri-
ers [71].
The presence of asymptomatic infections in Amazo-
nian communities suggests that, in fact, a similar phe-
nomenon may be occurring in areas of low P. vivax
transmission in Brazil. The gradual nature of the acquisi-
tion of this immunity is known to be partially mediated
by malaria specific antibodies responses, since passive
transfer of purified immunoglobulin from immune indi-
viduals rapidly reduces the recipient's parasitaemia [76].
Despite this, the factors that govern the development of
acquired immunity after natural infection remain poorly
understood. The identification of parasite antigens that
induce protective antibody and cellular responses would
be an important step toward understanding of naturally
acquired immunity to P. vivax malaria.
In Brazil, naturally occurring antibody to P. vivax
sporozoites have been reported since the late 1980s in
i n d i g e n o us  po p u l a t i o n  i n  t h e  S t a t e  o f  P a r a  B r a zi l  [ 7 7 ] .
Since then, polymorphism of the P. vivax CS protein of P.
vivax was reported and, in addition to parasites with the
original CS repeat amino acid sequences, designated P.
vivax VK210, a variant VK247 and P. vivax-like was also
described [78,79]. The human P. vivax-like parasite has a
CS repeat which corresponds to the simian parasite P.
simiovale. Otherwise the identity of these parasites is not
clear, since a line of the human isolates has not yet been
obtained and the clinical manifestation of this infection,
as well as that of VK247 variant is unknown.
In view of this finding, blood samples from the indige-
nous population mentioned above were re-examined and
high level of reactivity against the variants were detected.
These results demonstrated that these variants have been
present in Amazonian Indians for at least 12 years [80].
Other studies showed the occurrence of P. vivax variants
both by serology and PCR reaction in samples from dif-
ferent endemic regions in Brazil [14,48,81,82]. In non-
endemic regions, P. vivax and variants have been also
detected.
Studies on the naturally acquired humoral immune
responses to several P. vivax blood stage vaccine candi-
dates, such as PvMSP-1 (Merozoite Surface Protein 1),
PvAMA-1 (Apical Membrane Antigen 1), PvMSP-3
(Merozoite Surface Protein 3); PvMSP-9 (Merozoite Sur-
face Protein 9, RBP (Reticulocyte Binding Protein) and
DBP (Duffy Binding Protein) show that they are immuno-
genic in distinct Brazilian endemic areas with different
levels of exposure [63,74,83-91]. The specific antibodies
induced by natural infections to most of the proteins are
associated with time of exposure in endemic regions, a
phenomenon which has been frequently reported for var-
ious antigens reflecting most likely exposure to the para-
sites and possibly maturation of the immune system over
time. Although there is consistent evidence from human
and animal model system that cell-mediated immunity
may contribute both to protection and to pathogenesis,
the knowledge on cellular immune response in vivax
malaria and the factors that may regulate this immunity
are still poorly understood [92]. Very few studies have
been able to find a clear association between specific cel-
lular and antibodies to vaccine candidates and protection.
However, direct comparison of natural cellular and anti-
bodies responses to P. vivax antigens may provide valu-
able insight as to how a malaria vaccine might work.
Probably, an accumulation of a comprehensive repertoire
of antibodies recognizing antigenically distinct molecules
may be the key to acquisition of clinical protection.
Malaria research and teaching in Brazil
A survey of the groups working on different aspects of
malaria in Brazil was made in 2007 to facilitate and pro-
mote contacts with malariologists outside Brazil [93]. A
total of 70 groups were identified. From these, 46 were
considered to be effectively involved in conducting
research on malariology. Groups working with other
approaches, such as clinical, control, information, pre-
vention and therapeutics, without being, however,
directly concerned with research have also been listed.
The catalogue included a comprehensive classification ofOliveira-Ferreira et al. Malaria Journal 2010, 9:115
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the groups, according to the themes of interest and exper-
tise (considering that a group could be competent and
i n t e r e s t e d  i n  m o r e  t h a n  o n  s u b j e c t .  F i v e  g r o u p s  w e r e
working on biochemistry (including organic synthesis
and medicinal chemistry), five on cell biology, 15 on clini-
cal aspects, nine on diagnosis, 30 on drugs and therapeu-
tics (natural products, perspectives for drug
development, pharmacology, prophylaxis, chemo-resis-
tance and response monitoring), 17 on entomology and
vector control, 34 on epidemiology and control, 16 on
genetics and molecular biology (including recombinant
proteins and genetic polymorphisms), 19 on immunology
(immune protection, immune response, immunomodula-
tion, immunopathology and vaccine development and
testing in preclinical trials), five on parasitology and six
on pathogenesis and pathology.
It is important to point out that only 19% of these
research centres are located in the Amazon region (Fig-
ure 6). Despite occupying more than half (58%) of the
country territorial surface (approximately 8,511,965
square kilometers) and concentrating 99,8% of the regis-
tered cases of malaria, the region hosts only around 8% of
the urban and 12% of the total population of the country,
10% of the electorate in Brazil and accounts for about 5
percent of the nation's gross national product [94]. A vol-
ume of the catalogue can be obtained by request to the
corresponding author (CTDR).
Some teaching activities focusing specifically on mala-
riology are offered to students and graduates in Brazil.
Courses on host-parasite relationship, parasitology or
tropical medicine, that cover malaria together with other
parasitic and infectious diseases in the programme, are
not considered here. A two-week course (including prac-
tical classes on parasitological examination of blood
films) is offered yearly (in November) by the team of the
CPD-Mal to post-graduate (PG)(MSc and PhD) students
from the courses of IOC at Fiocruz and from other insti-
tutions [95]. A three-week course, also directed to PG
students (Course on Infectious and Parasitic Diseases at
the Faculty of Medicine of the University of São Paulo -
FM-USP, takes place at a biennial rhythm at the Instituto
de Medicina Tropical de São Paulo and is also opened to
students and graduates from other institutions [96]. A
one-week course on control of malaria vector, with
emphasis on biological control and practical field activi-
ties is offered yearly at the Instituto Nacional de Pesqui-
sas da Amazônia (end of October beginning
November)[97].
The Seminário Laveran & Deane sobre Malária is orga-
nized yearly by the CPD-Mal/Fiocruz, since 1995, to ana-
lyze and improve the project thesis of MSc and PhD
Brazilian students. The participants are confined in a
hotel (on the Itacuruçá Island) for five days, when the
projects are presented and discussed both in plenary and
in group discussion sections. Each student has two senior
tutors that follow the student for the duration of the sem-
inar, helping him/her in the composition of his/her final
report. The body of Professors also proposes a final
S e n i o r  R e p o r t  t o  e a c h  s t u d e n t .  T h e  Seminário  is sup-
ported mainly by the PNCM (as well as by the CNPq and
Faperj, and has also financial help from the French Gov-
ernment and the Sanofi-Aventis Impact Malaria Initia-
tive). The full methodology and a detailed description of
the dynamics of the Seminário can be found at its website
[95].
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